Avalo Therapeutics, Inc. (NASDAQ:AVTX) Short Interest Update

Key Points

• Avalo Therapeutics experienced a significant decrease in short interest, dropping 74.7% from 164,100 shares to 41,500 shares as of July 31st.
• The company reported a loss of ($1.92) earnings per share for the last quarter, which was worse than the consensus estimate of ($1.43).
• HC Wainwright upgraded Avalo Therapeutics from a "hold" to a "buy" rating with a price target of $15.00, as it maintains a consensus target price of $30.00.

Avalo Therapeutics, Inc. (NASDAQ:AVTX - Get Free Report) saw a large decline in short interest in the month of July. As of July 31st, there was short interest totaling 41,500 shares, adeclineof74.7% from the July 15th total of 164,100 shares. Based on an average daily volume of 154,900 shares, the short-interest ratio is presently 0.3 days. Approximately0.4% of the company's shares are sold short. Approximately0.4% of the company's shares are sold short. Based on an average daily volume of 154,900 shares, the short-interest ratio is presently 0.3 days.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Geode Capital Management LLC raised its stake in shares of Avalo Therapeutics by 937.0% during the fourth quarter. Geode Capital Management LLC now owns 104,853 shares of the company's stock valued at $779,000 after acquiring an additional 94,742 shares in the last quarter. Bank of Montreal Can bought a new stake in shares of Avalo Therapeutics during the fourth quarter valued at approximately $446,000. Walleye Capital LLC bought a new stake in shares of Avalo Therapeutics during the fourth quarter valued at approximately $145,000. Marshall Wace LLP bought a new stake in shares of Avalo Therapeutics during the fourth quarter valued at approximately $114,000. Finally, Tower Research Capital LLC TRC raised its stake in shares of Avalo Therapeutics by 998.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company's stock valued at $31,000 after acquiring an additional 3,754 shares in the last quarter. Hedge funds and other institutional investors own 87.06% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. HC Wainwright upgraded Avalo Therapeutics from a "hold" rating to a "buy" rating and set a $15.00 price target on the stock in a report on Monday, June 2nd. Cantor Fitzgerald initiated coverage on Avalo Therapeutics in a report on Friday. They set an "overweight" rating on the stock. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $30.00.

Avalo Therapeutics Price Performance

Shares of Avalo Therapeutics stock traded down $0.09 during trading hours on Tuesday, hitting $8.97. The company's stock had a trading volume of 11,659 shares, compared to its average volume of 114,110. The business has a 50 day moving average price of $6.16 and a two-hundred day moving average price of $6.04. Avalo Therapeutics has a 12-month low of $3.39 and a 12-month high of $16.00.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($1.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.43) by ($0.49). As a group, analysts expect that Avalo Therapeutics will post -19.07 earnings per share for the current fiscal year.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.